Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma TumorsBusiness Wire • 11/15/22
Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive YearBusiness Wire • 11/14/22
Castle Biosciences, Inc. (CSTL) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/02/22
Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell CarcinomaBusiness Wire • 10/31/22
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results (SEER) ProgramBusiness Wire • 10/27/22
New Data Demonstrate that the Utilization of TissueCypher® Barrett's Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett's Esophagus over the Standard of Care AloneBusiness Wire • 10/25/22
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk FactorsBusiness Wire • 10/24/22
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical ProcedureBusiness Wire • 10/20/22
Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2Business Wire • 10/19/22
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett's Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient ManagementBusiness Wire • 10/13/22
Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual MeetingBusiness Wire • 10/11/22
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual MeetingBusiness Wire • 10/10/22
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous MelanomaBusiness Wire • 09/23/22
Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 ConferenceBusiness Wire • 09/21/22
Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor DayBusiness Wire • 09/20/22
Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry AssociationBusiness Wire • 09/13/22
Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/12/22
American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett's EsophagusBusiness Wire • 08/04/22
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth ConferenceBusiness Wire • 08/03/22
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8Business Wire • 07/25/22
DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous MelanomaBusiness Wire • 07/25/22
